Pharmaceutical company
Appears in 3 stories
Developer of diranersen, advancing to registrational trials
For decades, nearly every Alzheimer's drug that reached patients aimed at one target: a sticky protein called amyloid. On July 14, 2026, Biogen showed the first clinical evidence that hitting a different protein, tau, can also slow the disease.
Updated Yesterday
Developer and commercial owner of salanersen
Some children with spinal muscular atrophy get a one-time gene therapy, then slowly weaken again. There has been no clear next step for them. On June 4, 2026, the FDA gave Biogen's salanersen a designation meant to speed up that next step.
Updated Jun 4
Co-developer with rights to zorevunersen outside North America
Dravet syndrome is a severe genetic epilepsy that causes hundreds of seizures per month, cognitive decline, and a 15–20 percent mortality rate. For nearly five decades, no treatment addressed the underlying cause — including two drugs approved in the past eight years, which could only partially suppress symptoms.
Updated May 30
No stories match your search
Try a different keyword
How would you like to describe your experience with the app today?
